Collectively, data obtained by in vivo treatment provide the functional confirmation of the ability of complementary treatment by CCL2/CCR2 axis blocking, in addition to MTX as a commonly recommended DMARD for RA treatment, to reduce osteoclast number and activity and therefore protect mice from arthritis-induced bone loss. This evidence concerns the gene CCL2 and arthritic joint disease.